688177 百奥泰
已收盘 05-26 15:00:00
资讯
新帖
简况
每周股票复盘：百奥泰（688177）戈利木单抗获FDA上市批准
证券之星 · 05-24 03:27
每周股票复盘：百奥泰（688177）戈利木单抗获FDA上市批准
百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书
智通财经 · 05-21
百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书
百奥泰（688177）披露2025年年度股东会决议公告，5月20日股价下跌1.16%
证券之星 · 05-20
百奥泰（688177）披露2025年年度股东会决议公告，5月20日股价下跌1.16%
百奥泰戈利木单抗生物类似药获FDA批准 成Simponi®及Simponi Aria®首个生物类似药；Accord Biopharma将在美商业化Immgolis™与Immgolis Intri™
美股速递 · 05-18
百奥泰戈利木单抗生物类似药获FDA批准 成Simponi®及Simponi Aria®首个生物类似药；Accord Biopharma将在美商业化Immgolis™与Immgolis Intri™
百奥泰（688177）披露戈利木单抗注射液获美国FDA上市批准公告，5月18日股价下跌0.61%
证券之星 · 05-18
百奥泰（688177）披露戈利木单抗注射液获美国FDA上市批准公告，5月18日股价下跌0.61%
百奥泰(688177.SH)：BAT2506获美国FDA上市批准
智通财经 · 05-18
百奥泰(688177.SH)：BAT2506获美国FDA上市批准
每周股票复盘：百奥泰（688177）注射用BAT8013获临床试验批准
证券之星 · 05-17
每周股票复盘：百奥泰（688177）注射用BAT8013获临床试验批准
百奥泰（688177）披露2025年年度股东会会议资料，5月13日股价下跌0.79%
证券之星 · 05-13
百奥泰（688177）披露2025年年度股东会会议资料，5月13日股价下跌0.79%
百奥泰(688177.SH)注射用BAT8013获得临床试验批准通知书
智通财经 · 05-12
百奥泰(688177.SH)注射用BAT8013获得临床试验批准通知书
百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%
证券之星 · 05-06
百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%
每周股票复盘：百奥泰（688177）股东户数增7.75%
证券之星 · 05-02
每周股票复盘：百奥泰（688177）股东户数增7.75%
百奥泰（688177）2026年一季报简析：增收不增利
证券之星 · 04-29
百奥泰（688177）2026年一季报简析：增收不增利
图解百奥泰年报：第四季度单季净利润同比增长25.45%
证券之星 · 04-28
图解百奥泰年报：第四季度单季净利润同比增长25.45%
每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益
证券之星 · 04-26
每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益
百奥泰拟4.5亿元出售贝塔宁权益 乐普药业接盘
中国经营报 · 04-15
百奥泰拟4.5亿元出售贝塔宁权益 乐普药业接盘
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
百奥泰（688177）披露BAT3306联合BAT8008治疗晚期实体瘤获临床试验批准，4月3日股价下跌2.8%
证券之星 · 04-03
百奥泰（688177）披露BAT3306联合BAT8008治疗晚期实体瘤获临床试验批准，4月3日股价下跌2.8%
百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书
智通财经网 · 04-02
百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书
每周股票复盘：百奥泰（688177）获STADA支付250万美元里程碑款
证券之星 · 03-29
每周股票复盘：百奥泰（688177）获STADA支付250万美元里程碑款
百奥泰最新公告：收到STADA支付的250万美元里程碑款
证券之星 · 03-26
百奥泰最新公告：收到STADA支付的250万美元里程碑款
加载更多
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是自身免疫药物、抗肿瘤药物。公司被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":19.51,"timestamp":1779778800000,"preClose":19.68,"halted":0,"volume":2404020,"delay":0,"changeRate":-0.0086,"floatShares":413999999,"shares":413999999,"eps":-0.943,"marketStatus":"已收盘","change":-0.17,"latestTime":"05-26 15:00:00","open":19.79,"high":19.85,"low":19.23,"amount":46876800,"amplitude":0.0315,"askPrice":19.51,"askSize":7,"bidPrice":19.47,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-0.943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":5,"adr":0,"adjPreClose":19.68,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779759000000,1779766200000],[1779771600000,1779778800000]],"highLimit":21.65,"lowLimit":17.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":36.05,"roa":"--","roe":"--","epsLYR":-0.8,"committee":0.708207,"marketValue":8079000000,"turnoverRate":0.0058,"status":1,"afterMarket":{"amount":0,"volume":0,"close":19.51,"buyVolume":0,"sellVolume":0,"time":1779780837558,"indexStatus":"已收盘 05-26 15:30:00","preClose":19.68},"floatMarketCap":8079000000},"requestUrl":"/m/hq/s/688177","defaultTab":"news","newsList":[{"id":"2637375535","title":"每周股票复盘：百奥泰（688177）戈利木单抗获FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637375535","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637375535?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:27","pubTimestamp":1779564431,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，百奥泰报收于20.1元，较上周的19.58元上涨2.66%。本周关注点来自公司公告汇总：百奥泰戈利木单抗注射液获美国FDA上市批准，适应症为类风湿关节炎和溃疡性结肠炎。公司公告汇总百奥泰生物制药股份有限公司收到美国食品药品监督管理局通知，其戈利木单抗注射液已获准上市。BAT2206已获美国FDA和欧洲EMA批准上市，并在全球71个国家和地区达成商业化授权合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637892813","title":"百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637892813","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637892813?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:34","pubTimestamp":1779356051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到了国家药品监督管理局核准签发的关于乌司奴单抗注射液和乌司奴单抗注射液的《药品注册证书》。BAT2206是百奥泰根据NMPA、美国食品药品监督管理局、欧洲药品管理局生物类似药相关指导原则开发的乌司奴单抗注射液，乌司奴单抗是一款靶向白细胞介素IL-12和IL-23共有的 p40 亚基的全人源单克隆抗体。截至本公告披露日，BAT2206已获得FDA和EMA批准上市，美国注册商品名称为Starjemza，欧洲注册商品名为Usymro。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845313","title":"百奥泰（688177）披露2025年年度股东会决议公告，5月20日股价下跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845313?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:18","pubTimestamp":1779272303,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，百奥泰报收于19.57元，较前一交易日下跌1.16%，最新总市值为81.04亿元。百奥泰于近日披露《2025年年度股东会决议公告》。公告显示，公司于2026年5月19日召开2025年年度股东会，会议审议通过了《关于公司2025年年度报告及其摘要的议案》《关于公司2025年度董事会工作报告的议案》《关于公司2025年度利润分配预案的议案》等九项议案。出席会议的股东及代理人共131人，代表有表决权股份总数的70.3817%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110463142","title":"百奥泰戈利木单抗生物类似药获FDA批准 成Simponi®及Simponi Aria®首个生物类似药；Accord Biopharma将在美商业化Immgolis™与Immgolis Intri™","url":"https://stock-news.laohu8.com/highlight/detail?id=1110463142","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110463142?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:00","pubTimestamp":1779105640,"startTime":"0","endTime":"0","summary":"百奥泰的戈利木单抗生物类似药已获得美国食品药品监督管理局（FDA）的批准，成为强生旗下Simponi®及Simponi Aria®的首个生物类似药。根据协议，Accord Biopharma将负责在美国市场商业化这两款产品，即Immgolis™（戈利木单抗-Sldi）与Immgolis Intri™（戈利木单抗-Sldi）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636027640","title":"百奥泰（688177）披露戈利木单抗注射液获美国FDA上市批准公告，5月18日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636027640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636027640?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:58","pubTimestamp":1779101895,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，百奥泰报收于19.46元，较前一交易日下跌0.61%，最新总市值为80.58亿元。该股当日开盘19.61元，最高19.63元，最低19.21元，成交额达3674.5万元，换手率为0.46%。近日，百奥泰生物制药股份有限公司披露关于Immgolis/ Immgolis Intri获美国FDA上市批准的公告。公告显示，公司收到美国食品药品监督管理局通知，其戈利木单抗注射液已获准上市。产品已获FDA和EMA批准，正在多个国家和地区申报上市，并已与多家企业达成商业化授权合作，覆盖118个国家和地区。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800030119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636024622","title":"百奥泰(688177.SH)：BAT2506获美国FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636024622","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636024622?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:58","pubTimestamp":1779098337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到美国食品药品监督管理局签发的关于Immgolis/Immgolis Intri上市批准通知。据悉，BAT2506是百奥泰根据中国国家药品监督管理局、FDA、欧洲药品管理局生物类似药相关指导原则开发的戈利木单抗生物类似药。截至本公告披露日，BAT2506已获得FDA、EMA上市批准，美国商品名为Immgolis/Immgolis Intri，欧洲注册商品名为Gotenfia;已向NMPA、巴西国家卫生监督局等递交上市许可申请，目前正在评审中。BAT2506的商业化授权合作目前已覆盖118个国家和地区。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK4588","LABU","IPOS","BK4585","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636314062","title":"每周股票复盘：百奥泰（688177）注射用BAT8013获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636314062","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636314062?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:13","pubTimestamp":1778962389,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，百奥泰报收于19.58元，较上周的20.04元下跌2.3%。本周，百奥泰5月12日盘中最高价报20.78元。本周关注点公司公告汇总：百奥泰注射用BAT8013获药物临床试验批准，拟用于治疗晚期或转移性实体瘤。公司公告汇总：百奥泰召开2025年年度股东会，审议年度报告、利润分配预案等多项议案。百奥泰自愿披露关于注射用BAT8013获得药物临床试验批准通知书的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785302","title":"百奥泰（688177）披露2025年年度股东会会议资料，5月13日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635785302?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:34","pubTimestamp":1778668475,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，百奥泰报收于20.05元，较前一交易日下跌0.79%，最新总市值为83.02亿元。该股当日开盘20.38元，最高20.38元，最低19.74元，成交额达4893.29万元，换手率为0.59%。百奥泰于2026年5月13日披露《2025年年度股东会会议资料》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300034736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634978022","title":"百奥泰(688177.SH)注射用BAT8013获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2634978022","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634978022?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:02","pubTimestamp":1778580137,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品注射用BAT8013用于治疗晚期或转移性实体瘤患者的临床试验申请获得批准。BAT8013通过与细胞表面的CD25特异性结合，经受体介导的内吞作用进入细胞内部，在溶酶体环境中，其连接子被组织蛋白酶切割，释放出细胞毒载荷Exatecan。该机制既能选择性清除肿瘤微环境中的调节性T细胞，改善肿瘤免疫抑制微环境，也能直接杀伤CD25肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633390184","title":"百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633390184","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633390184?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:50","pubTimestamp":1778064627,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，百奥泰报收于20.23元，较前一交易日下跌1.8%，最新总市值为83.77亿元。公告显示，公司于2026年4月30日召开第二次临时股东会，审议通过了《关于转让药品品种权益及相关资产与业务的议案》。出席会议的股东及代理人共114人，代表有表决权股份288,959,575股，占公司总表决权股份的69.7835%。该议案为普通决议议案，已获出席会议股东所持有效表决权过半数通过，表决结果为同意285,349,592股，占98.7507%；反对3,606,883股，占1.2482%；弃权3,100股，占0.0011%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632640905","title":"每周股票复盘：百奥泰（688177）股东户数增7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632640905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632640905?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:52","pubTimestamp":1777668729,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，百奥泰报收于20.6元，较上周的22.22元下跌7.29%。本周，百奥泰4月27日盘中最高价报22.58元。业绩披露要点：2026年一季报显示，百奥泰归母净利润为-1.52亿元，同比下降62.68%。股本股东变化截至2026年3月31日，百奥泰股东户数为9898.0户，较2025年12月31日增加712.0户，增幅7.75%。表决结果为同意285,349,592股，占98.7507%；反对3,606,883股，占1.2482%；弃权3,100股，占0.0011%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631741530","title":"百奥泰（688177）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2631741530","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631741530?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:53","pubTimestamp":1777420434,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百奥泰发布2026年一季报。根据财报显示，百奥泰增收不增利。其中，毛利率81.34%，同比增5.65%，净利率-60.35%，同比减33.57%，销售费用、管理费用、财务费用总计9730.62万元，三费占营收比38.68%，同比增3.41%，每股净资产0.54元，同比减63.54%，每股经营性现金流0.11元，同比减42.59%，每股收益-0.37元，同比减60.87%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-35.49%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900024272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319027","title":"图解百奥泰年报：第四季度单季净利润同比增长25.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319027","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630319027?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:45","pubTimestamp":1777311959,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰2025年年报显示，当年度公司主营收入9.35亿元，同比上升25.84%；归母净利润-3.32亿元，同比上升34.95%；扣非净利润-4.26亿元，同比上升23.38%；其中2025年第四季度，公司单季度主营收入2.52亿元，同比上升55.58%；单季度归母净利润-1.08亿元，同比上升25.45%；单季度扣非净利润-1.47亿元，同比上升2.65%；负债率83.56%，投资收益83.39万元，财务费用1748.1万元，毛利率78.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800004856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630480802","title":"每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630480802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630480802?lang=zh_cn&edition=full","pubTime":"2026-04-26 05:20","pubTimestamp":1777152023,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，百奥泰报收于22.22元，较上周的23.03元下跌3.52%。本周，百奥泰4月20日盘中最高价报23.27元。本周关注点公司公告汇总：百奥泰拟向乐普药业转让贝塔宁品种权益及相关资产，交易总金额为4.5亿元。公司公告汇总百奥泰生物制药股份有限公司拟向乐普药业股份有限公司转让贝塔宁品种权益及相关资产与业务，交易总金额（含税）为人民币4.5亿元，分五期支付，并按年度净销售额的个位数百分比收取销售分成，最长分成期为10年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406558","title":"百奥泰拟4.5亿元出售贝塔宁权益 乐普药业接盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406558","media":"中国经营报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627406558?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:14","pubTimestamp":1776233640,"startTime":"0","endTime":"0","summary":"4月14日晚间，百奥泰发布公告称，公司拟以4.5亿元（含税）向乐普医疗控股子公司乐普药业股份有限公司转让贝塔宁品种权益及相关资产与业务，并签署《贝塔宁制剂及原料药品种转让协议》。据百奥泰公告披露，2025年度贝塔宁的销售收入占公司营业总收入比重较小，本次转让不会对公司正常生产经营造成重大不利影响。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-15/doc-inhuqfve3511738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756325.SGD","688177","002437","LU0154236417.USD","600513","LU1093756168.USD","BK4588","BK4532","BK4007","REGN","NVO","BK4599","IE00BZ1G4Q59.USD","603087","300558","NVOX","02196","301087","IE00BKVL7J92.USD","600196","NVOH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651552","title":"百奥泰（688177）披露BAT3306联合BAT8008治疗晚期实体瘤获临床试验批准，4月3日股价下跌2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651552?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:06","pubTimestamp":1775210782,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，百奥泰报收于22.56元，较前一交易日下跌2.8%，最新总市值为93.42亿元。百奥泰生物制药股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司研发的BAT3306注射液联合注射用BAT8008在晚期实体瘤患者中开展临床试验。BAT3306为帕博利珠单抗的生物类似药，属于PD-1免疫检查点抑制剂；BAT8008为靶向Trop-2的抗体药物偶联物，拟用于实体肿瘤治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624774145","title":"百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624774145","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624774145?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:54","pubTimestamp":1775123652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品BAT3306注射液联合注射用BAT8008用于治疗晚期实体瘤患者的临床试验申请获得批准。帕博利珠单抗是一种人源化单克隆抗体药物，属于免疫检查点抑制剂。BAT8008是百奥泰开发的靶向Trop2的抗体药物偶联物，拟开发用于实体肿瘤治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333496","title":"每周股票复盘：百奥泰（688177）获STADA支付250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333496","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333496?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:43","pubTimestamp":1774730588,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百奥泰报收于22.29元，较上周的22.08元上涨0.95%。本周，百奥泰3月27日盘中最高价报22.46元。协议首付款及里程碑款总金额最高达1.575亿美元，包括1000万美元首付款和累计不超过1.475亿美元的里程碑付款，以及基于净销售额的两位数百分比分成。公司近日收到STADA支付的250万美元里程碑款，实际到账金额扣除银行手续费。截至公告日，BAT2506已获欧洲EMA批准上市，商品名为Gotenfia，并已向中国NMPA、美国FDA、巴西ANVISA提交上市申请，目前处于评审中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622685631","title":"百奥泰最新公告：收到STADA支付的250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2622685631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622685631?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:10","pubTimestamp":1774519821,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，公司近日收到STADA就BAT2506(戈利木单抗)注射液授权许可协议支付的250万美元里程碑付款(扣除银行手续费前)。该协议于2024年5月28日签署，授予STADA在欧盟、英国、瑞士等欧洲国家的独占商业化权益，首付款及里程碑款总额最高达1.575亿美元，并含净销售额两位数百分比的收入分成。目前，BAT2506已获欧洲EMA批准上市，商品名为Gotenfia，并已向中国NMPA、美国FDA、巴西ANVISA提交上市申请，正在评审中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600034336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779810263358,"stockEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":-0.1143},{"period":"3month","weight":-0.164},{"period":"6month","weight":-0.2206},{"period":"1year","weight":-0.1572},{"period":"ytd","weight":-0.1495}],"compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0178},{"period":"3month","weight":0.0085},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2402},{"period":"ytd","weight":0.0463}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9898人(较上一季度增加7.75%)","perCapita":"41834股","listingDate":"2020-02-21","address":"广东省广州市海珠区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是自身免疫药物、抗肿瘤药物。公司被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}